HDAC8: Histone deacetylase 8
Histone deacetylase that catalyzes the deacetylation of lysine residues on the N-terminal part of the core histones (H2A, H2B, H3 and H4).
- Drugs that act on it: 1
- Approved: 0
- In phases 1 to 3: 1
- Sponsors: 1
Who is on it, and how far along
Every drug ChEMBL records acting on HDAC8, by the furthest stage it has reached for any use, coloured by modality.
How to read this
Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.
- Small molecule 1
| Drug | Furthest stage | Sponsor | Modality | Action | Open trials |
|---|---|---|---|---|---|
| Mocetinostat | Phase 2 | Mirati Therapeutics | Small molecule | InhibitorHistone deacetylase 8 inhibitor | 2 |
| Mocetinostat With Vinorelbine in Children, Adolescents & Young Adults With Refractory and/or Recurrent Rhabdomyosarcoma | Mocetinostat | Phase 1 | Active, not recruiting | Jonsson Comprehensive Cancer Center | Mar 6, 2020 |
| Pembrolizumab (Immunotherapy Drug) in Combination With Guadecitabine and Mocetinostat (Epigenetic Drugs) for Patients With Advanced Lung Cancer. | Mocetinostat | Phase 1 | Active, not recruiting | Memorial Sloan Kettering Cancer Center | Jul 18, 2017 |
- Cornelia de Lange syndrome0.83
- Wilson-Turner syndrome0.59
- Neoplasm0.56
- Plasma cell myeloma0.55
- Hereditary disease0.54
- Duchenne muscular dystrophy0.52
- Peripheral T-cell lymphoma, not otherwise specified0.52
- Intellectual disability0.50
- Mature T-cell and NK-cell non-Hodgkin lymphoma0.50
- Primary cutaneous T-cell non-Hodgkin lymphoma0.49
- T-cell non-Hodgkin lymphoma0.48
- 3q26 microduplication syndrome0.46
Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL3192, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-22. Gene name, function (UniProt Q9BY41, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets